Date: 2013-06-04
Type of information: Series A financing round
Company: Autifony Therapeutics (UK)
Investors: Pfizer Venture Investments (USA)
Amount: £5.5 million (€ 6.4 million)
Funding type: series A financing round
Planned used:
Others: Autifony Therapeutics has launched phase I clinical study of Kv3 potassium channel modulator, AUT00063. AUT00063 is being developed as a treatment for age-related hearing loss and tinnitus.To fund this lead programme through to clinical Proof-of-Concept for at least one hearing disorder indication, Autifony has nnounced that Pfizer Venture Investments, the venture capital arm of Pfizer Inc., has invested £5 million to join existing investors SV Life Sciences, Imperial Innovations plc and UCL Business plc (UCL-B) in the Series A financing round. Dr Elaine Jones from Pfizer has joined the Autifony board. The International Biotechnology Trust PLC (IBT) has also invested, bringing the total funds raised to date to £15.75 million.
Therapeutic area: Otorhinolaryngology
